Turning Back Time: A Comprehensive List of Interventions that Decrease Next-Generation Epigenetic Aging Clocks in Humans

Key Takeaways

• Semaglutide cuts DunedinPACE aging pace by 9% in 32 weeks.
• FTC/TAF reduces DNAm PhenoAge by over six years in 12 weeks.
• Omega‑3 supplementation lowers multiple epigenetic clocks by up to six years.
• Caloric restriction slows aging rate by up to 3% over two years.
• NR, rapamycin and senolytics showed no effect on next‑gen clocks.

Pulse Analysis

The emergence of next‑generation epigenetic clocks marks a paradigm shift in how researchers quantify biological aging. Unlike first‑generation models that merely predict chronological age, clocks such as GrimAge, OMICmAge and DunedinPACE are calibrated against mortality risk and clinical biomarkers, making them sensitive to interventions that genuinely alter physiological decline. This sensitivity enables trials to detect modest yet meaningful changes in aging trajectories, turning molecular readouts into actionable endpoints for drug development and lifestyle programs.

The review’s headline‑grabbing results highlight semaglutide’s 9% reduction in the DunedinPACE pace of aging, positioning the GLP‑1 agonist as a front‑runner among pharmacologic geroprotectors. Equally striking are the large absolute age reversals observed with FTC/TAF—over six years of DNAm PhenoAge in just three months—and consistent benefits from omega‑3 fatty acids across multiple cohorts. These findings reinforce the value of repurposing existing, FDA‑approved drugs and nutraceuticals, offering a faster, lower‑cost pathway to translate aging science into clinical practice.

Conversely, the analysis debunks the hype surrounding many experimental compounds. Nicotinamide riboside, rapamycin and popular senolytic blends failed to shift any next‑generation clock, underscoring the gap between animal models and human efficacy. Moreover, interventions like therapeutic plasmapheresis may even worsen epigenetic age, warning clinicians to scrutinize mechanistic plausibility before adoption. As the field matures, robust clock‑based endpoints will likely become standard in longevity trials, helping investors allocate capital toward interventions with demonstrable, quantifiable impact on human healthspan.